Understanding how TRIM29 contributes to bladder cancer invasion
Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder Cancer
This study is looking at how a protein called TRIM29 affects the growth of bladder cancer, especially how it helps tumors become more aggressive, with the hope of finding new ways to treat and prevent the spread of the disease for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10907853 on NIH RePORTER |
What this research studies
This research investigates the role of TRIM29, a protein that plays a significant part in bladder cancer progression, particularly in how it influences the transition from non-invasive to invasive tumors. By using advanced models, the research aims to uncover the mechanisms by which TRIM29 affects tumor formation and resistance to treatments. The goal is to identify potential therapeutic targets that could help prevent the aggressive spread of bladder cancer, ultimately improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle-invasive bladder cancer who are at risk of metastasis.
Not a fit: Patients with non-invasive bladder tumors or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent the progression of bladder cancer to its more aggressive forms.
How similar studies have performed: Other research has shown promise in targeting molecular drivers of cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Palmbos, Phillip L — University of Michigan at Ann Arbor
- Study coordinator: Palmbos, Phillip L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.